Posted by Michael Wonder on 13 Mar 2020
ICER releases evidence report on treatments for sickle cell disease
12 March 2020 - Three new treatments use different mechanisms to improve patient outcomes, offering important options for patients.
The Institute for Clinical and Economic Review (ICER) today released an Evidence Report assessing the comparative clinical effectiveness and value of treatments for sickle cell disease, including crizanlizumab (Adakveo, Novartis), voxelotor (Oxbryta, Global Blood Therapeutics), and L-glutamine (Endari, Emmaus Life Sciences).
Due to public health concerns regarding meetings and travel during the ongoing COVID-19 situation, ICER will not be hosting an in-person public meeting to discuss these treatments.
